AHI and Nexus-Vita to fast track integration

|

Published 22-JUN-2021 12:45 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Advanced Human Imaging Limited (ASX:AHI) opened in positive territory after management announced that the company had signed a binding agreement with Nexus Vita Pte Ltd (Nexus-Vita), a Singapore-based health monitoring and management technology company.

Importantly, the agreement announced today it is for the completion of the Nexus-Vita application is a separate agreement and no changes have been made to the initial binding term sheet entered into with Nexus-Vita and announced to the ASX on 6 October 2020.

This deal was projected to generate annual recurring revenue of US$3.58 million for AHI.

Harking back to the agreement just struck, Nexus Vita has engaged AHI to conclude the integration of the AHI CompleteScan Face and Body Scan capabilities into its application.

Unfortunately, Nexus-Vita has been plagued over the last 6 months with rolling lockdowns in both Japan and Singapore, causing numerous delays and loss of development staff, whilst trying to complete the acquisition and development of the Nexus-Vita application.

Nexus-Vita has agreed today to pay AHI a fixed amount of USD$500,000 for the completion of the integration to be performed by the AHI development team, ending the delays and extension sought throughout the past 6 months.

From an operational perspective Nexus-Vita has completed the initial medical health monitoring, prevention and engagement platform which is now ready to have the CompleteScan integrated in readiness for release to the customers of Nexus-Vita.

Nexus Vita app addresses health management and record-keeping

Nexus-Vita has created an application for users to track and manage all facets of their health and health records.

The platform is a proprietary state-of-the-art health management and personal record keeping system in a single digital environment, allowing users to save their records (both medical and health basis) in a single, easy to access digital platform.

The data spans multiple environments from wearable data to training, nutrition and care programs, while also allowing the user to share information with their doctor, healthcare provider, personal trainer or chronic disease management specialist.

Nexus-Vita plans to substantially improve user-to-professional data sharing and management.

The group believes this will improve lifetime health, reduce the need for medical interventions, and save cost and resources for the user and health systems through its partnership with AHI and use of the integrated CompleteScan platform.

Nexus-Vita and AHI will collaborate on this final step to integrate the CompleteScan platform into all of Nexus-Vita’s verticals, commencing with an initial integration into its pre-emptive health platform using FaceScan and BodyScan.

Market ready integration to occur by August

Under the terms of the binding agreement, AHI will deliver a market-ready integration into the Nexus-Vita platform by 31 August 2021.

Commenting on these developments, Vlado Bosanac chairman and chief executive officer of AHI said, “Bringing the integration to my team will not only deliver a world class integration, but it will also negate concerns many shareholders have aired due to the rolling delays and extensions we have granted over the past 6 months.

"Nexus-Vita has never waivered from its genuine commitment to the transaction and its enthusiasm for the capture suite that the AHI technology brings to the table.

"The group understands they are losing valuable time in market due to these delays and having the AHI team conclude the integrations brings not only certainty but quality assurance.

"Nexus Vita wants to take advantage of the global need and growth that the digital health sector is experiencing.

"The world has experienced significant disruption with individuals reluctant to attend medical facilities and the compounding strain being experienced by the healthcare system worldwide as a result of the current pandemic.

"I am pleased to be working with Jeff and the Nexus-Vita team to provide the CompleteScan platform capabilities to their unique intervention, monitoring and pre-emptive health solution”.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X